Epilepsy Market to Register Incremental Growth During the Forecast Period (2023-2032), Analyses DelveInsight | Neurocrine Bioscience, Takeda, Ovid Therapeutics, UCB Biopharma, Zynerba

(Albany, USA) DelveInsight's "Epilepsy Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Epilepsy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Epilepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [https://www.delveinsight.com/report-store/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Epilepsy Overview

According to the National Institute of Neurological Disorders and Stroke (NINDS), epilepsies are a spectrum of brain disorders ranging from severe, life-threatening, and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness.

Some of the key facts of the Epilepsy Market Report:

* The Epilepsy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
* UC acquired Zogenix to strengthen Epilepsy pipeline and Zogenix's Fintepla gained FDA approval for LGS in March 2022
* Ztalmy gained FDA nod to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)
* Ovid Therapeutics has partnered with AstraZeneca for exclusive access to a library of early-stage small molecules that target the KCC2 transporter, including OV350
* The total prevalent population of Epilepsy in the 7MM was found to be 7,342,223 in 2021
* The total 7MM diagnosed prevalent cases of Epilepsy in 2021 were 5,552,142 out of which the highest diagnosed prevalent cases of this disease were seen in the United States, which was 3,015,300 in 2021
* According to the Centers for Disease Control and Prevention (CDC) (2017) also highlights that in 2015, 1.2% of the US population had active epilepsy, which suggests that about 3.4 million people suffer from epilepsy nationwide: 3 million adults and 470,000 children
* Key Epilepsy Companies: Neurocrine Bioscience, Takeda/ Ovid Therapeutics, UCB Biopharma, Zynerba Pharma, Aquestive Therapeutics, PTC Therapeutics, Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, CombiGene, and others
* Key Epilepsy Therapies: NBI-921352, Soticlestat, Staccato Alprazolam, Zygel, ACT-709478/ NBI-827104, Libervant, Vatiquinone, and others
* The Epilepsy epidemiology based on gender analyzed that epilepsy is more prevalent among males than in females

Get a Free sample for the Epilepsy Market Report - [https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key benefits of the Epilepsy Market report:

* Epilepsy market report covers a descriptive overview and comprehensive insight of the Epilepsy Epidemiology and Epilepsy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
* The Epilepsy market report provides insights on the current and emerging therapies.
* Epilepsy market report provides a global historical and forecasted market covering drug outreach in 7MM.
* The Epilepsy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Epilepsy market.

Download the report to understand which factors are driving Epilepsy epidemiology trends @ [https://www.delveinsight.com/report-store/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Epilepsy Market

The dynamics of the Epilepsy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

"According to the estimates, the highest market size of Epilepsy was found in theUnited States And the least was in France and Spain across the 7MM. Besides, the upcoming therapies ofEpilepsy are expected to combat the current unmet needs faced by the patients with Epilepsy and add to the overall growth of the Epilepsy market size."

Epilepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epilepsy Epidemiology Segmentation:

The Epilepsy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of Epilepsy
* Prevalent Cases of Epilepsy by severity
* Gender-specific Prevalence of Epilepsy
* Diagnosed Cases of Episodic and Chronic Epilepsy

Epilepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched during the study period. The analysis covers Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epilepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Epilepsy market share @ [https://www.delveinsight.com/report-store/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Epilepsy Therapies and Key Companies

* NBI-921352: Neurocrine Bioscience
* Soticlestat: Takeda/ Ovid Therapeutics
* Staccato Alprazolam: UCB Biopharma
* Zygel: Zynerba Pharma
* ACT-709478/ NBI-827104: Neurocrine Biosciences
* Libervant: Aquestive Therapeutics
* Vatiquinone: PTC Therapeutics

Epilepsy Market Strengths

* Several epilepsy centers are working towards recognizing and addressing pseudo-pharmaco-resistance faced to patients due to AEDs
* The epilepsy pipeline possess several high phase drugs with Libervant and Ganaxolone being the most promising ones with the best results.

Scope of the Epilepsy Market Report

* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Epilepsy Companies: Neurocrine Bioscience, Takeda/ Ovid Therapeutics, UCB Biopharma, Zynerba Pharma, Aquestive Therapeutics, PTC Therapeutics, Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, CombiGene, and others
* Key Epilepsy Therapies: NBI-921352, Soticlestat, Staccato Alprazolam, Zygel, ACT-709478/ NBI-827104, Libervant, Vatiquinone, and others
* Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
* Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Epilepsy Unmet Needs, KOL's views, Analyst's views, Epilepsy Market Access and Reimbursement

To know more about Epilepsy treatment, visit @ [https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Epilepsy Market Opportunities

* Even after the presence of several approved therapies, there still exists a large window for novel therapies that can overcome the high rate of pharmaco-resistance to AEDs inepileptic patients
* The current understanding of specific rare variations of epilepsy has recently enabled developers to test novel mechanisms in high-need patient populations like Dravet syndrome and LGS

Table of Contents

1. Epilepsy Market Report Introduction

2. Executive Summary for Epilepsy

3. SWOT analysis of Epilepsy

4. Epilepsy Patient Share (%) Overview at a Glance

5. Epilepsy Market Overview at a Glance

6. Epilepsy Disease Background and Overview

7. Epilepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Epilepsy

9. Epilepsy Current Treatment and Medical Practices

10. Epilepsy Unmet Needs

11. Epilepsy Emerging Therapies

12. Epilepsy Market Outlook

13. Country-Wise Epilepsy Market Analysis (2019-2032)

14. Epilepsy Market Access and Reimbursement of Therapies

15. Epilepsy Market Drivers

16. Epilepsy Market Barriers

17. Epilepsy Appendix

18. Epilepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epilepsy-market-to-register-incremental-growth-during-the-forecast-period-20232032-analyses-delveinsight-neurocrine-bioscience-takeda-ovid-therapeutics-ucb-biopharma-zynerba]
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services



This release was published on openPR.